Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER), in Patients With Recurrent and/or Refractory Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER), in Patients With Recurrent and/or Refractory Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA 401 (Primary)
  • Indications Head and neck cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Immatics N.V.

    • Most Recent Events

    • 18 Jul 2024 According to an Immatics N.V. media release, the first proof-of-concept clinical data for its next-generation, half-life extended TCR Bispecific molecule, TCER IMA401 (MAGEA4/8), will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 on Monday, September 16, 2024.
    • 21 Mar 2024 According to Immatics N.V. media release, First clinical data in at least 25 patients in dose escalation across multiple solid cancers is expected to be announced in 2H 2024.
    • 14 Nov 2023 According to Immatics N.V. media release, first clinical data is expected to be announced in 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top